Alcohol septal ablation versus surgical septal myectomy of obstructive hypertrophic cardiomyopathy: systematic review and meta-analysis
European Journal of Cardio-Thoracic Surgery · 01.03.2023 · 63 (3)
DOI: 10.1093/ejcts/ezad043 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Cardio-Thoracic Surgery, online erschienen am 14.02.2023. Verfasst von Yujiro Yokoyama und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, St. Luke's University Health Network, Bethlehem, PA, USA. Hauptthemen laut MEDLINE: Cardiac Surgical Procedures, Cardiomyopathy, Hypertrophic, Ablation Techniques. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 64 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES To elucidate the optimal septal reduction therapy for obstructive hypertrophic cardiomyopathy, we conducted a meta-analysis comparing alcohol septal ablation (ASA) and septal myectomy. METHODS MEDLINE, EMBASE and Cochrane CENTRAL were searched to identify studies investigating the outcomes of ASA and septal myectomy in patients with obstructive hypertrophic cardiomyopathy in January 2023. The primary outcome of interest was all-cause mortality in studies with ≥1 year of follow-up. The secondary outcomes of interest comprised left ventricular outflow tract (LVOT) pressure gradient reduction and reoperations of LVOT. A subgroup analysis of all-cause mortality including studies with follow-up ≥5 years was performed. RESULTS 27 observational studies were included (15 968 patients). Analysis demonstrated similar all-cause mortality [hazard ratio (HR) (95% confidence interval) (CI) 1.24 (0.88–1.76); P = 0.21; I2 = 56%]. In contrast, ASA was associated with less reduction of LVOT pressure gradient and a reoperation rate [weighted mean difference (95% CI) 11.04 mmHg (5.60–16.48); P < 0.01; I2 = 64%, HR (95% CI) 9.14 (6.55–12.75); P < 0.001; I2 = 0%, respectively]. The subgroup analysis with follow-up ≥5 years revealed higher long-term mortality with ASA [HR (95% CI) 1.50 (1.04–2.15); P = 0.03; I2 = 52%]. CONCLUSIONS Although both septal reduction therapies were associated with similar all-cause mortality, ASA was associated with a higher rate of reoperation and less reduction of LVOT pressure gradient. Furthermore, all-cause mortality with follow-up ≥5 years showed favourable outcomes with septal myectomy, although the result is only hypothesis-generating given a subgroup analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, St. Luke's University Health Network, Bethlehem, PA, USA.
- School of Medicine, University of Tsukuba, Ibaraki, Japan.
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
- Department of Surgery, Division of Cardiothoracic Surgery, Emory University, Atlanta, GA, USA.
- Department of Surgery, Columbia University Irving Medical Center, New York, NY, USA.
- Department of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
ORCID-Profile: Tomonari Shimoda, Keitaro Akita, Toshiki Kuno
Zitieren
APA
Yokoyama, Y., Shimoda, T., Shimada, Y. J., Shimamura, J., Akita, K., Yasuda, R., Takayama, H., & Kuno, T. (2023). Alcohol septal ablation versus surgical septal myectomy of obstructive hypertrophic cardiomyopathy: systematic review and meta-analysis. European Journal of Cardio-Thoracic Surgery, 63(3). https://doi.org/10.1093/ejcts/ezad043
Vancouver
Yokoyama Y, Shimoda T, Shimada YJ, Shimamura J, Akita K, Yasuda R, et al. Alcohol septal ablation versus surgical septal myectomy of obstructive hypertrophic cardiomyopathy: systematic review and meta-analysis. European Journal of Cardio-Thoracic Surgery. 2023;63(3). doi:10.1093/ejcts/ezad043
BibTeX
@article{Yokoyama2023,
author = {Yokoyama, Yujiro and Shimoda, Tomonari and Shimada, Yuichi J and Shimamura, Junichi and Akita, Keitaro and Yasuda, Risako and Takayama, Hiroo and Kuno, Toshiki},
title = {Alcohol septal ablation versus surgical septal myectomy of obstructive hypertrophic cardiomyopathy: systematic review and meta-analysis},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2023},
volume = {63},
number = {3},
doi = {10.1093/ejcts/ezad043}
}
EUVIMED